Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

In light of increasingly stringent sustainability requirements, bio/pharma companies need to make sure they formulate effective ESG strategies.

Setting Goals for Sustainability

CMOs are hoping to grow outsourcing to significantly higher levels in many different areas, with a focus on analytical testing, toxicity testing, and fill/finish operations.

The Growth and Emergence of Technology in the Outsourcing Space

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

Pedestrians as Priority

Cheryl Barton is director of PharmaVision, 

TreeFrog Therapeutics is leaping ahead in cell therapies through 
resources such as new technologies and investor partnerships.


Frontrunners in the Latest Stem Cell Technology

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.

Getting Personal for Blockbusters in 2023

Bianca Piachaud-Moustakis is lead writer at Pharmavision, Pharmavision.co.uk.

Does the new regulatory framework have the potential to incentivise R&D investment in rare diseases?

Revision of the Orphan Medicines Regulation

Mike Hennessy Jr. is the Chairman and CEO of 

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Paradigm Shift

Additionally, 89 human medicines have been recommended for approval by the EMA, and the organization also analyzed a new vaccine against dengue and two diabetes treatments that address important public health issues outside the EU.

EMA Executive Director Sends Message of Promoting Stronger Public Presence for Safety, Efficacy of Medicines

In addition, the Clinical Trials Regulation is set to become a single-entry point for sponsors and regulators in January 2023 for the submission and assessment of all new clinical trials.

Highlights of December 2022 EMA Management Board Meeting 

In terms of extensions, the committee recommended Adcirca, Dupixent, Edistride, Enhertu, Fintepla, Forxiga, Hemlibra, Imfinzi (including two new indications), Kerendia, Spikevax and Triumeq.

News